Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

REGENXBIO Inc. - Common Stock (NQ:RGNX)

11.60 +0.05 (+0.43%)
Streaming Delayed Price Updated: 3:37 PM EST, Nov 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 311,574
Open 11.55
Bid (Size) 11.60 (100)
Ask (Size) 11.62 (100)
Prev. Close 11.55
Today's Range 11.42 - 12.01
52wk Range 5.035 - 13.93
Shares Outstanding 43,466,186
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
REGENXBIO INC (NASDAQ:RGNX) Tops Q3 2025 Estimates, Shares Rise on Strong Results and Pipeline Progress
REGENXBIO beats Q3 2025 earnings estimates with strong revenue and a narrower loss. Key gene therapy RGX-202 advances, with topline data expected in early 2026. 
Via Chartmill
Earnings Scheduled For November 6, 2025
 
Via Benzinga

Performance

YTD
+47.6%
+47.6%
1 Month
+2.3%
+2.3%
3 Month
+43.2%
+43.2%
6 Month
+41.8%
+41.8%
1 Year
+0.3%
+0.3%

More News

Read More
The Analyst Verdict: Regenxbio In The Eyes Of 7 Experts
Via Benzinga
7 Analysts Assess Regenxbio: What You Need To Know
Via Benzinga
A Glimpse Into The Expert Outlook On Regenxbio Through 6 Analysts
Via Benzinga
Regenxbio Unveils 12-Month Data For Gene Therapy Soon After FDA Delays Review Date
Via Benzinga
Analyst Expectations For Regenxbio's Future
Via Benzinga
Earnings Scheduled For August 7, 2025
Via Benzinga
Earnings Scheduled For May 12, 2025
Via Benzinga
What to Expect from Regenxbio's Earnings
Via Benzinga
Navigating the Currents: Top Sectors Primed for Growth in Q3 2025
Via MarketMinute
Topics Artificial Intelligence Economy Retirement
FDA Extends Decision Date On Regenxbio's Gene Therapy Into Next Year
Via Benzinga
REGENXBIO INC (NASDAQ:RGNX) Reports Q2 2025 Earnings Miss, Stock Slides Amid Revenue and EPS Shortfalls
Via Chartmill
Topics Earnings
A Glimpse Into The Expert Outlook On Regenxbio Through 8 Analysts
Via Benzinga
Crude Oil Moves Higher; Ciena Posts Downbeat Earnings
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Early Wins: RegenXBio's Gene Therapy Helps Duchenne Patients Walk Stronger, Longer
Via Benzinga
Dow Dips Over 100 Points; US Jobless Claims Increase
Via Benzinga
Topics Stocks
Which stocks are gapping on Thursday?
Via Chartmill
Vera Therapeutics, Applied Digital, Kymera Therapeutics And Other Big Stocks Moving Higher On Monday
Via Benzinga
The One-Minute Market Report - Saturday, April 26
Via Talk Markets
Topics ETFs Stocks / Equities
Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost
Via Investor's Business Daily
Topics Government
What's going on in today's after hours session
Via Chartmill
Chewy, Bausch Health Companies And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
Regenxbio Touts Positive Biomarker Data From Duchenne Muscular Dystrophy Gene Therapy Trial
Via Benzinga

Frequently Asked Questions

Is REGENXBIO Inc. - Common Stock publicly traded?
Yes, REGENXBIO Inc. - Common Stock is publicly traded.
What exchange does REGENXBIO Inc. - Common Stock trade on?
REGENXBIO Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for REGENXBIO Inc. - Common Stock?
The ticker symbol for REGENXBIO Inc. - Common Stock is RGNX on the Nasdaq Stock Market
What is the current price of REGENXBIO Inc. - Common Stock?
The current price of REGENXBIO Inc. - Common Stock is 11.60
When was REGENXBIO Inc. - Common Stock last traded?
The last trade of REGENXBIO Inc. - Common Stock was at 11/12/25 03:37 PM ET
What is the market capitalization of REGENXBIO Inc. - Common Stock?
The market capitalization of REGENXBIO Inc. - Common Stock is 504.21M
How many shares of REGENXBIO Inc. - Common Stock are outstanding?
REGENXBIO Inc. - Common Stock has 504M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.